Verona scores FDA approval for Ohtuvayre as COPD maintenance therapy
Ohtuvayre is expected to rake in $1.1bn in global sales from the market for COPD patients with moderate to severe exacerbations by 2029.
Ohtuvayre is expected to rake in $1.1bn in global sales from the market for COPD patients with moderate to severe exacerbations by 2029.
What's Your Reaction?
